Table 1.

Population/intervention/comparator/outcome/study design and search criteria for the SLR

Criteria	Inclusion
Study design	Randomized controlled trials above phase I (including crossover studies up to time of crossover)
Population	Adult patients (aged ≥ 18 years) with moderately-to-severely active RA who have had inadequate response to ≥ 1 csDMARDs Adult patients (aged ≥ 18 years) with moderately-to-severely active RA who have had inadequate response to ≥ 1 TNFα-inhibitors
Treatment/intervention	Interventions of interest (at any dosage or administration type)a:
	Sarilumab (REGN88, SAR153191) Adalimumab (Humira) Certolizumab (Cimzia) Etanercept (Enbrel) Golimumab (Simponi) Infliximab (Remicade) Abatacept (Orencia) Rituximab (MabThera/Rituxan)	Tocilizumab (RoActemra/Actemra) Tofacitinib (Xeljanz) SB4 (Samsung Bioepis) GP2015 (Sandoz) ABP501 (Amgen) BI695501 (Boehringer) SB5 (Samsung Bioepis) Remsima (CT-P13)	SB2 (Samsung Bioepis) Inflectra (CT-P13) Flixabi (Biogen) Rituxan (GP2013) Baricitinib (LY3009104, INCB028050)
Comparator	Placebo or any of the above listed treatments as monotherapy
Outcomes	Efficacy, safety and patient reported outcomes at 24 weeks (± 4 weeks) and 52 weeks (± 8 weeks)
Time	No limit
Language	English language

cs Conventional synthetic, DMARD disease-modifying antirheumatic drug, RA rheumatoid arthritis, TNF tumor necrosis factor

^aOnly interventions with global regulatory approval were included